School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, 266001, China.
School of Health and Life Sciences, University of Health and Rehabilitation Sciences, Qingdao, 266001, China.
Eur J Med Chem. 2023 Mar 5;249:115128. doi: 10.1016/j.ejmech.2023.115128. Epub 2023 Jan 26.
Like tuberculosis and Acquired Immune Deficiency Syndrome (AIDS), hepatitis B is a globally recognized major public health threat. Although there are many small-molecule drugs for the treatment of hepatitis B, the approved drugs cannot eradicate the pathogenic culprit covalently closed circular DNA in patients, so the patients need long-term medication to control HBV amplification. Driven by a high unmet medical need, many pharmaceutical companies and research institutions have been engaged in the development of anti-HBV drugs to achieve a functional cure for chronic hepatitis B as soon as possible. This review summarizes the pathogenesis of hepatitis B virus and the research progress in the development of anti-HBV small molecule drugs, and introduces the cccDNA formation and transcription inhibitors and core inhibitors in detail, especially emphasizes the role of chinese herbal medicine in the treatment of chronic hepatitis B. Furthermore, this review proposes three potential strategies for cccDNA eradication in the future. We believe this review will provide meaningful guidance to achieve a functional cure for viral hepatitis B in the future.
与结核病和获得性免疫缺陷综合征（AIDS）一样，乙型肝炎也是一种全球公认的主要公共卫生威胁。虽然有许多治疗乙型肝炎的小分子药物，但已批准的药物并不能消除患者体内共价闭合环状 DNA 的致病元凶，因此患者需要长期用药来控制 HBV 扩增。由于存在巨大的未满足的医疗需求，许多制药公司和研究机构一直在致力于开发抗乙型肝炎病毒药物，以尽快实现慢性乙型肝炎的功能性治愈。本综述总结了乙型肝炎病毒的发病机制和抗乙型肝炎病毒小分子药物的研发进展，详细介绍了 cccDNA 形成和转录抑制剂以及核心抑制剂，特别强调了中草药在慢性乙型肝炎治疗中的作用。此外，本综述还提出了未来消除 cccDNA 的三种潜在策略。我们相信，这篇综述将为未来实现乙型肝炎的功能性治愈提供有意义的指导。
